BRG
DFTX

Bay Rivers Group’s Definium Therapeutics DFTX Stock Holding History

Bay Rivers Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
31,208
+4,862
+18% +$120K 0.5% 39
2026
Q1 		$498K Buy
26,346
+10,345
+65% +$176K 0.21% 68
2025
Q4 		$214K Buy
16,001
+2,000
+14% +$24.8K 0.09% 91
2025
Q3 		$165K Buy
14,001
+2,383
+21% +$22.2K 0.07% 88
2025
Q2 		$75.4K Buy
+11,618
New +$76.4K 0.03% 87

Other funds holding DFTX

PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
SCI
Stableford Capital II Scottsdale, Arizona $289M AUM 20.84% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Bay Rivers Group's DFTX Position: Q2 2026 in Review

Bay Rivers Group increased its Definium Therapeutics (DFTX) stake by 18% in Q2 2026, buying an estimated $120K and bringing the position to 31,208 shares worth $1.47M. The position accounts for 0.5% of the portfolio, ranked #39.

Bay Rivers Group first reported a position in DFTX in Q2 2025 and has held it in 5 quarters since. 17 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Bay Rivers Group held 31,208 shares of Definium Therapeutics worth $1.47M as of Q2 2026.
  • Bay Rivers Group bought 4,862 Definium Therapeutics shares in Q2 2026, an estimated $120K.
  • Definium Therapeutics made up 0.5% of Bay Rivers Group's portfolio in Q2 2026, its #39 holding.
  • Bay Rivers Group first reported a position in Definium Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 17 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Bay Rivers Group's 13F filing for Q2 2026, filed 9 Jul 2026.